New York- and Alabama-based IN8bio is leveraging gamma-delta (γδ) T cell biology to merge innate and adaptive immune capabilities against cancer. Has some of the early excitement in the cell ...

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...

Our novel gamma-delta T cell engager platform, presented for the first time at AACR 2025, demonstrates how we can combine the innate tumor-recognition capabilities of gamma-delta T cells with the ...

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...

(RTTNews) - IN8bio, Inc. (INAB) announced the launch of its next-generation Gamma-Delta T-cell engager or TCE platform INB-600, designed to overcome the limitations of existing Gamma-Delta TCE ...

Takeda has announced a $100 million collaboration with Abingworth to work with GammaDelta Therapeutics, a UK biotech which is pioneering a novel type of T cell therapy. The Japanese pharma company ...

GammaDelta Therapeutics has developed a pipeline of novel allogeneic cell therapies based on its Vδ1+ γδ T cell platforms for the treatment of solid tumors and beyond. Gamma delta (γδ) T ...

Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biopharmaceutical company with a market capitalization of $65.5 million, focuses on developing engineered gamma-delta T cell therapies. The company ...

Japanese drugmaker Takeda has said it will exercise its option to buy UK-based GammaDelta Therapeutics, a specialist in 'off-the-shelf' cell therapies for solid tumours and blood cancers.

Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biopharmaceutical company with a market capitalization of $65.5 million, focuses on developing engineered gamma-delta T cell therapies. The company ...